atezolizumab
Showing 76 - 100 of 400
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma Trial in United States (Atezolizumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Bladder Cancer
- +2 more
- Atezolizumab
- +2 more
-
Hartford, Connecticut
- +10 more
Nov 23, 2022
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma Trial in Boston (Atezolizumab, Bevacizumab, Stereotactic Beam
Recruiting
- Hepatocellular Carcinoma
- Resectable Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Feb 10, 2022
Tumors Trial in China (Atezolizumab)
Recruiting
- Neoplasms
- Atezolizumab
-
Beijing City, China
- +16 more
Jan 12, 2023
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)
Active, not recruiting
- EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
- Atezolizumab
- +4 more
-
Großhansdorf, Germany
- +17 more
Jan 12, 2023
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma Trial run by the NCI
Recruiting
- Advanced Alveolar Soft Part Sarcoma
- +3 more
- Atezolizumab
- +5 more
-
Bethesda, Maryland
- +1 more
Jan 28, 2023
Small Cell Lung Cancer Recurrent Trial in Goyang-si (Atezolizumab)
Recruiting
- Small Cell Lung Cancer Recurrent
- Atezolizumab
-
Goyang-si, Gyeonggi-do, Korea, Republic ofNational Cancer Center
Apr 4, 2022
Squamous Cell Carcinoma of Head and Neck Trial in Aurora, Colorado Springs, Highlands Ranch (Atezolizumab, Stereotactic Body
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- Atezolizumab
- Stereotactic Body Radiation Therapy
-
Aurora, Colorado
- +3 more
Jun 15, 2022
Cutaneous Melanoma Trial in Houston (Atezolizumab)
Recruiting
- Cutaneous Melanoma
- Atezolizumab
-
Houston, TexasHouston Methodist Hospital
Dec 28, 2021
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
HER2-positive Metastatic Breast Cancer, CNS Metastases Trial in Chicago, Boston (ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB)
Active, not recruiting
- HER2-positive Metastatic Breast Cancer
- Central Nervous System Metastases
- ATEZOLIZUMAB
- +2 more
-
Chicago, Illinois
- +1 more
Mar 14, 2022
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Frankfurt, Bern (Atezolizumab, 5-Fluorouracil, Calciumfolinat)
Active, not recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Atezolizumab
- +4 more
-
Frankfurt, Germany
- +1 more
Apr 14, 2022
NSCLC Stage IV Trial in Bellinzona, Chur, Geneva (Atezolizumab)
Recruiting
- NSCLC Stage IV
- Atezolizumab
-
Bellinzona, Switzerland
- +2 more
Apr 26, 2022
Urothelial/Bladder Cancer, Nos Trial in New York (Atezolizumab, PGV001, Poly ICLC)
Completed
- Urothelial/Bladder Cancer, Nos
- Atezolizumab
- +3 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Mar 7, 2022
Advanced NSCLC Trial in Orlando, Pittsburgh (Atezolizumab)
Completed
- Advanced Non-small Cell Lung Cancer
- Atezolizumab
-
Orlando, Florida
- +1 more
Apr 10, 2022
Head and Neck Tumors Trial in France (Atezolizumab, Bevacizumab)
Active, not recruiting
- Head and Neck Neoplasms
- Atezolizumab
- Bevacizumab
-
Lyon, France
- +6 more
May 16, 2022
Tumors Trial in China (Atezolizumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Neoplasms
- Atezolizumab
- +2 more
-
Beijing, China
- +6 more
Jul 20, 2022
Solid Tumor, Metastatic Cancer Trial in United States (TJ004309, Atezolizumab)
Active, not recruiting
- Solid Tumor
- Metastatic Cancer
- TJ004309
- Atezolizumab
-
Birmingham, Alabama
- +3 more
Mar 31, 2022
Colorectal Cancer Trial in Essen (Atezolizumab)
Recruiting
- Colorectal Cancer
- Atezolizumab
-
Essen, GermanyWestdeutsches Tumorzentrum
Feb 14, 2022
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma Trial in
Recruiting
- Extensive Stage Lung Small Cell Carcinoma
- +5 more
- Atezolizumab
- Temozolomide
-
Indianapolis, Indiana
- +2 more
Oct 26, 2022
Refractory Diffuse Large B Cell Lymphoma Trial in United States (KTE-C19, Atezolizumab, Cyclophosphamide)
Active, not recruiting
- Refractory Diffuse Large B Cell Lymphoma
- KTE-C19
- +3 more
-
Duarte, California
- +4 more
Apr 27, 2022